相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CSNK2 in cancer: pathophysiology and translational applications
Scott W. Strum et al.
BRITISH JOURNAL OF CANCER (2022)
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
Nuria Profitos-Peleja et al.
CANCERS (2022)
Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments
Preetesh Jain et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
Zaira Spinello et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma
Sabrina Manni et al.
FRONTIERS IN ONCOLOGY (2021)
Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation
Juan Lazaro-Navarro et al.
BLOOD ADVANCES (2021)
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Dana Prukova et al.
CLINICAL CANCER RESEARCH (2019)
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies
Fevzi F. Yalniz et al.
DRUGS (2019)
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study
Matthew S. Davids et al.
LANCET HAEMATOLOGY (2019)
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Oshrat Hershkovitz-Rokah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V. Pham et al.
CLINICAL CANCER RESEARCH (2018)
CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death
Elisa Mandato et al.
CURRENT CANCER DRUG TARGETS (2018)
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Swathi Balaji et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases
Romina Mancinelli et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2017)
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Xiaohong Zhao et al.
NATURE COMMUNICATIONS (2017)
Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways
Sabrina Manni et al.
Oncotarget (2017)
Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
Julie M. Vose
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2017)
Targeting CK2-driven non-oncogene addiction in B-cell tumors
E. Mandato et al.
ONCOGENE (2016)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth
Marco Pizzi et al.
ONCOTARGET (2015)
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2
S. Manni et al.
LEUKEMIA (2014)
Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells
Sabrina Manni et al.
PLOS ONE (2013)
Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress-Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response
Sabrina Manni et al.
CLINICAL CANCER RESEARCH (2012)
On CK2 regulation of chronic lymphocytic leukemia cell viability
Leila R. Martins et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
A Peptide-Based Target Screen Implicates the Protein Kinase CK2 in the Global Regulation of Caspase Signaling
James S. Duncan et al.
SCIENCE SIGNALING (2011)
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death
Francesco Piazza et al.
BMC CANCER (2010)
CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy
Adam Siddiqui-Jain et al.
CANCER RESEARCH (2010)
Activity of protein kinase CK2 uncouples Bid cleavage from caspase-8 activation
Christian T. Hellwig et al.
JOURNAL OF CELL SCIENCE (2010)
A MicroRNA Screen to Identify Modulators of Sensitivity to BCL2 Inhibitor ABT-263 (Navitoclax)
Lloyd T. Lam et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells
Giovanni Di Maira et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt
Dong Bai et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
mTORC1 promotes survival through translational control of Mcl-1
John R. Mills et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
mir-29 regulates Mcl-1 protein expression and apoptosis
J. L. Mott et al.
ONCOGENE (2007)
Translational repression of MCL-1 couples stress-induced eIF2α phosphorylation to mitochondrial apoptosis initiation
Ralph M. Fritsch et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8
S Desagher et al.
MOLECULAR CELL (2001)
Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II
D Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
